The DCPS Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T-cell leukemia line, designed to disrupt the gene encoding the mRNA decapping scavenger DCPS. This polyclonal pool provides a heterogeneous loss-of-function model for investigating DCPS-mediated regulation of mRNA turnover without the constraints of clonal selection. The knockout cells serve as a versatile tool for examining the downstream consequences of impaired cap hydrolysis in a T-lymphocyte context, facilitating studies in RNA biology, cancer research, and neurodevelopmental disorders.
The Jurkat cell line is an established suspension culture of CD4+ T-cell origin that expresses the TCR/CD3 complex and is widely used as a model for T-cell signaling and apoptosis. These cells recapitulate key aspects of T-lymphocyte activation and programmed cell death, making them particularly suitable for dissecting the intersection of mRNA metabolism and immune cell function. The integration of a DCPS knockout in this well-characterized background enables precise examination of how mRNA decapping scavenger activity influences T-cell homeostasis and response pathways.
DCPS functions as the terminal enzyme in the 3??-to-5?? mRNA degradation pathway, hydrolyzing the residual m7G cap structure that remains following deadenylation and decapping by the DCP1/DCP2 complex. This reaction is essential for complete nucleotide recycling and for preventing the accumulation of cap analogs that can interfere with translation. DCPS operates within a broader network that includes the exosome complex, the 5??-to-3?? exonuclease XRN1, and deadenylases, coordinating with nonsense-mediated decay and general RNA degradation pathways. Its activity is upregulated by cellular stress pathways and is sensitive to the small-molecule inhibitor RG3039. Consequently, loss of DCPS leads to global alterations in mRNA stability and translation efficiency, affecting gene expression profiles critical for cellular function.
In Jurkat T-cells, DCPS knockout disrupts the normal clearance of capped mRNA decay intermediates, potentially altering the expression of genes involved in T-cell receptor signaling, cytokine production, and apoptosis. This model is highly relevant for exploring the molecular basis of Al-Raqad syndrome, a neurodevelopmental disorder linked to DCPS mutations that causes intellectual disability and seizures. Although the disease primarily manifests in neuronal tissues, the Jurkat knockout system offers a tractable platform to investigate DCPS-dependent pathways that may converge on immune and neurological crosstalk. Additionally, the model supports research into the role of mRNA turnover in T-cell leukemogenesis, where dysregulated gene expression is a hallmark.
Typical applications include measuring mRNA decay rates using transcriptional inhibition assays, quantifying m7G cap accumulation, and evaluating sensitivity to the DCPS inhibitor RG3039 to validate target engagement. The polyclonal knockout population is well-suited for RNA-sequencing experiments to chart transcriptome-wide changes, and for functional assays such as Western blotting, RT-qPCR, apoptosis induction, and T-cell activation studies. Researchers can employ these cells to elucidate how DCPS modulates translation efficiency and gene expression under basal and stress conditions, and to screen for modulators of DCPS activity. For further details and custom configurations, please contact Ascent Research.
